How Does Dextromethorphan Work for Depression?

Dextromethorphan fights depression by blocking a type of brain receptor called NMDA and activating another called sigma-1, both of which influence the neurotransmitter glutamate. This is a fundamentally different approach from conventional antidepressants, which primarily target serotonin, norepinephrine, or dopamine. The approved formulation pairs dextromethorphan with bupropion, and the reason for that pairing is pharmacological, not just additive: bupropion prevents the body from breaking dextromethorphan down too fast, keeping enough of it in circulation to actually reach the brain in useful amounts.

Working Through Glutamate Instead of Serotonin

Most antidepressants prescribed over the past few decades work by altering the levels or activity of monoamine neurotransmitters like serotonin and norepinephrine. Dextromethorphan takes a different route. It acts as an uncompetitive antagonist at NMDA receptors, meaning it gets into the receptor channel when it’s open and reduces activity without fully shutting the receptor down.¹ NMDA receptors play a central role in glutamate signaling, which is the brain’s primary excitatory system. When NMDA receptor activity is dampened in the right way, it appears to trigger a cascade of downstream changes that can lift depressive symptoms.

Alongside NMDA blockade, dextromethorphan activates sigma-1 receptors. These receptors sit on the membranes of cells in the brain and act as modulators of multiple signaling pathways. Preclinical research has shown that dextromethorphan’s antidepressant-like effects in animal models can be weakened when sigma-1 receptors are blocked, suggesting these receptors are not just bystanders but active contributors to the drug’s mood-lifting effects.² Sigma-1 activation is thought to influence how neurons handle stress, manage calcium signaling, and regulate the release of other neurotransmitters. The combination of NMDA antagonism and sigma-1 agonism is what makes dextromethorphan’s pharmacology distinctive among antidepressants.

Why Bupropion Comes With It

If dextromethorphan is the active player against depression, bupropion’s primary job in the combination is to keep dextromethorphan from being destroyed too quickly. When you swallow dextromethorphan on its own, a liver enzyme called CYP2D6 rapidly converts it into dextrorphan, a different compound with a different pharmacological profile. This metabolism is so efficient that very little unchanged dextromethorphan reaches the bloodstream in most people. Bupropion is a potent inhibitor of CYP2D6, so it slows that conversion and allows dextromethorphan plasma levels to rise high enough to be therapeutically relevant.³

Bupropion also has its own antidepressant activity. It inhibits the reuptake of norepinephrine and dopamine, and it has been used as a standalone antidepressant for decades. So the combination is not purely a pharmacokinetic trick; both drugs contribute to the antidepressant effect. But clinical trials specifically tested whether the combination outperforms bupropion alone, and it did. In a phase 2 trial, patients receiving dextromethorphan-bupropion (45 mg dextromethorphan, 105 mg bupropion) had significantly greater reductions in depression scores compared to those receiving bupropion by itself.⁴ That comparison matters because it demonstrates that the glutamate-targeting action of dextromethorphan adds something on top of what bupropion already does.

The dose of bupropion in the approved combination (105 mg) is lower than the typical standalone antidepressant dose (150 to 450 mg), which further supports the idea that bupropion’s main role here is metabolic gatekeeper rather than primary antidepressant.⁵

A Faster Onset Than Traditional Antidepressants

One of the most talked-about features of dextromethorphan-bupropion is speed. Traditional serotonin-targeting antidepressants generally take four to eight weeks before patients feel meaningful improvement. In both phase 2 and phase 3 clinical trials of dextromethorphan-bupropion, measurable improvements in depression rating scores appeared within two weeks of starting treatment.³ That does not mean the drug works overnight, but it does compress the waiting period considerably.

The rationale for faster onset ties back to the mechanism. Drugs that modulate glutamate signaling, especially through NMDA receptor blockade, appear to trigger more rapid changes in neural circuitry than drugs working through monoamines. Dextromethorphan shares pharmacological properties with ketamine, which is the most prominent example of a rapid-acting antidepressant. Researchers have hypothesized that dextromethorphan’s NMDA and sigma-1 activity could produce similarly fast responses.⁶ A case report documented a patient with treatment-resistant depression who experienced antidepressant effects within 48 hours of dextromethorphan administration, with effects lasting about seven days from a single dose and up to 20 days with daily dosing.⁷ That is a single patient, so it is not proof of anything general, but it aligns with what the mechanistic picture would predict.

How It Compares to Ketamine

The ketamine comparison is inevitable because both drugs block NMDA receptors, and ketamine has become the reference point for rapid-acting antidepressants. But the two drugs are not interchangeable, and the differences matter practically.

In preclinical studies, both dextromethorphan and ketamine reduced depression-like behavior in mice (measured by immobility in a forced-swim test), but they diverged in other ways. Ketamine increased general locomotor activity, while dextromethorphan did not, suggesting different effects on arousal and stimulation. Ketamine also rapidly increased levels of a growth-factor precursor called pro-BDNF in the hippocampus within 40 minutes, while dextromethorphan did not produce the same rapid change in either the hippocampus or the frontal cortex within that timeframe.⁸ This suggests dextromethorphan may achieve its antidepressant effects through a partially overlapping but not identical set of brain changes.

A key clinical difference is that ketamine and its derivative esketamine produce dissociative side effects: feelings of detachment, perceptual distortions, and sometimes hallucinations. Dextromethorphan does not produce these effects at therapeutic antidepressant doses. Recent research points to a possible explanation rooted in which NMDA receptor subtypes each drug prefers. Both ketamine and dextromethorphan dampen tonic currents mediated by NR2C/D-containing NMDA receptors, which appears to drive antidepressant effects. But ketamine and esketamine also have a strong affinity for NR2A/B subtypes, and that additional interaction may be what generates dissociation.⁹ In practical terms, this means dextromethorphan-bupropion can be taken at home as a daily oral pill, while ketamine and esketamine typically require in-office administration with monitoring for dissociative episodes.

What the Evidence Looks Like for Treatment-Resistant Depression

Treatment-resistant depression, broadly defined as depression that has not responded to two or more adequate antidepressant trials, is where the need for new treatments is most acute. The evidence for dextromethorphan-bupropion specifically in this population is still early-stage and comes mainly from case reports and small series rather than large controlled trials.

A report from India described three patients with treatment-resistant depression who were given dextromethorphan-bupropion, either alone or in combination with other medications, and showed satisfactory responses within two weeks.¹⁰ Separately, a case report documented a patient who had failed adequate trials of multiple antidepressants and experienced rapid improvement within 48 hours of starting dextromethorphan, with the effect sustained for up to 20 days on daily dosing before gradually fading.⁷

There has also been interest in combining dextromethorphan-bupropion with esketamine for people who have not responded to either drug alone. A three-patient case series explored this approach and found that two of the three patients showed clinical improvement with the combination, while the third, who had the most severe treatment resistance, did not respond to either agent alone or together. No significant adverse events were reported across the three patients.¹¹ Three patients is far too few to draw firm conclusions, but the absence of safety red flags when combining two NMDA-targeting agents is at least somewhat reassuring for future research.

The honest assessment here is that dextromethorphan-bupropion’s approval was based on trials in major depressive disorder generally, not specifically in treatment-resistant populations. Evidence for the treatment-resistant subgroup is suggestive and mechanistically plausible, but it consists mostly of small, uncontrolled observations. Larger trials focused on this population would be needed before anyone could say the drug reliably works where others have failed.

Anti-Inflammatory Effects That May Help the Brain

Beyond its receptor-level actions, dextromethorphan appears to have anti-inflammatory properties in the brain. This matters because neuroinflammation is increasingly recognized as a factor in depression for at least a subset of patients. Elevated inflammatory markers in the blood and brain have been linked to depressive symptoms, and some researchers believe that dampening brain inflammation could be one pathway to antidepressant effects.

Laboratory research has shown that dextromethorphan suppresses the activation of microglia, the brain’s resident immune cells. When microglia become overactivated, they release inflammatory molecules like tumor necrosis factor alpha (TNF-alpha), which can damage neurons and disrupt signaling. In a study using primary rat microglia exposed to an inflammatory trigger, dextromethorphan suppressed TNF-alpha expression and reduced downstream cell-death signaling. The researchers found that dextromethorphan accomplished this partly through changes in how DNA-packaging proteins (histones) were modified, essentially dialing down the gene expression that drives inflammation.¹²

This anti-inflammatory angle is still being explored in humans and has not been established as a confirmed mechanism of dextromethorphan’s antidepressant action. But it adds another dimension to the drug’s profile and could help explain why some patients respond to it when they have not responded to purely monoamine-targeting drugs.

Your Genetics Can Change How the Drug Affects You

Because CYP2D6 is the enzyme that metabolizes dextromethorphan, and because people carry different genetic variants of CYP2D6, the same dose of dextromethorphan can produce very different blood levels in different individuals. People are generally classified along a spectrum from poor metabolizers (who break the drug down slowly) to extensive or ultra-rapid metabolizers (who break it down quickly).

Research has shown the differences can be dramatic. In one study, peak plasma levels of unchanged dextromethorphan were roughly five-fold higher in poor metabolizers compared to extensive metabolizers. The metabolite dextrorphan, meanwhile, was about 30-fold lower in poor metabolizers. These differences translated into real differences in how people felt. At higher doses, poor metabolizers experienced more psychomotor impairment, more sedation, and more dysphoria than extensive metabolizers, while also reporting less euphoria and less overall drug liking.¹³

In the approved dextromethorphan-bupropion combination, bupropion’s CYP2D6 inhibition is meant to level this playing field somewhat by slowing metabolism across the board. But it does not erase the underlying variability entirely. Someone who is already a poor metabolizer and then takes a CYP2D6 inhibitor on top of that will end up with even higher dextromethorphan levels than intended. This is one reason clinicians need to be aware of a patient’s other medications, since several common drugs (certain antidepressants, antipsychotics, and heart medications) also inhibit CYP2D6 and could compound the effect.

Pharmacogenomic testing for CYP2D6 is available and is sometimes used in psychiatry to guide dosing decisions. For dextromethorphan-bupropion specifically, knowing whether a patient is a poor metabolizer could help anticipate side effects or adjust doses, though formal guidelines on genotype-based dosing for this particular combination are still evolving.

A Drug With Several Lives

Dextromethorphan’s journey to becoming an antidepressant is unusually circuitous even by pharmaceutical standards. It was first developed as a cough suppressant and has been available over the counter in that role for decades. It was later combined with quinidine (another CYP2D6 inhibitor, performing the same metabolic-gatekeeper role that bupropion serves in the depression formulation) and approved for pseudobulbar affect, a condition involving uncontrollable episodes of laughing or crying that are out of proportion to a person’s actual emotional state.¹⁴ The dextromethorphan-quinidine combination has also been investigated for managing agitation in dementia, a notoriously difficult symptom to treat without heavy sedation.¹⁵

The thread connecting these seemingly unrelated uses is the same core pharmacology: NMDA antagonism, sigma-1 agonism, and anti-inflammatory properties. Pseudobulbar affect involves dysregulated emotional expression circuits that NMDA modulation can stabilize. Dementia-related agitation involves overexcited neural pathways that benefit from the same kind of dampening. Depression involves dysfunctional glutamate signaling and, in some patients, neuroinflammation. The same molecular toolkit turns out to be useful across all three conditions, which is why dextromethorphan kept getting repurposed rather than one specific version of it being designed from scratch for each condition.

The fact that dextromethorphan has been used safely as an over-the-counter cough medicine for over 60 years gave researchers and regulators a head start on safety data. Its side-effect profile at therapeutic doses is well characterized. At the doses used for depression (45 mg twice daily in the approved formulation), the most commonly reported side effects in clinical trials included dizziness, nausea, diarrhea, and headache. The dissociative and hallucinogenic effects that have made dextromethorphan a drug of abuse in much higher recreational doses are not seen at antidepressant-range doses, especially when paired with the controlled delivery that the bupropion combination provides. That said, serotonin syndrome remains a risk when dextromethorphan is combined with other serotonergic drugs, and prescribers are expected to screen for potential interactions before starting treatment.